Combination Study of Panitumumab and Regorafenib in Advanced or Metastatic KRAS and NRAS Wild Type Colorectal Cancers

Trial Profile

Combination Study of Panitumumab and Regorafenib in Advanced or Metastatic KRAS and NRAS Wild Type Colorectal Cancers

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs Panitumumab (Primary) ; Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Sep 2016 Status changed from active, no longer recruiting to discontinued.
    • 03 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 30 Jul 2015 NRAS wild type colorectal cancers was included along with KRAS in patient indication, study title and inclusion and exclusion criteria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top